Search Results - "Ito, Mototsugu"

A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects by Ito, Mototsugu, Spence, Anna, Blauwet, Mary Beth, Heo, Nakyo, Goldwater, Ronald, Maruff, Paul, Marek, Gerard J

“…Background: ASP8062 is a novel orally active GABAB receptor positive allosteric modulator in clinical development for the treatment of alcohol use disorder…”
Get full text

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opioid users by Ito, Mototsugu, Walzer, Mark, Blauwet, Mary Beth, Spence, Anna, Heo, Nakyo, Kelsh, Debra, Blahunka, Paul, Erdman, Jay, Alsharif, Mohamad Nour, Marek, Gerard J

“…Background: Recent increases in opioid use and subsequent opioid use disorder are a major public health crisis in the United States. Aims: This phase 1…”
Get full text

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder by Ito, Mototsugu, Walzer, Mark, Beth Blauwet, Mary, Spence, Anna, Heo, Nakyo, Kelsh, Debra, Blahunka, Paul, Erdman, Jay, Nour Alsharif, Mohamad, Marek, Gerard J

“…Background: There is an unmet need for therapeutics with greater efficacy and tolerability for the treatment of opioid use disorder (OUD). ASP8062 is a novel…”
Get full text

Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) by OSE, Atsushi, ITO, Mototsugu, KUSUHARA, Hiroyuki, YAMATSUGU, Kenzo, KANAI, Motomu, SHIBASAKI, Masakatsu, HOSOKAWA, Masakiyo, SCHUETZ, John D, SUGIYAMA, Yuichi

“…[3 R ,4 R ,5 S ]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802) is a pharmacologically active form of the…”
Get full text

Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality by Maass, Katie F., Barfield, Matthew D., Ito, Mototsugu, James, Christopher A., Kavetska, Olga, Kozinn, Marc, Kumar, Parag, Lepak, Maureen, Leuthold, Luc Alexis, Li, Wenkui, Mikhailov, Dmitri, Patel, Shefali, Perez, Nisha L., Jackson Rudd, Deanne, Vakkalagadda, Blisse, Williams, Tracy M., Zha, Jiuhong, Zhang, Xin, Anderson, Melanie D.

“…Advances in the technologies to enable patient‐centric sampling (PCS) have the potential to improve blood sample collection by enabling clinical trial…”
Get full text

Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802 by Ito, Mototsugu, Kusuhara, Hiroyuki, Ose, Atsushi, Kondo, Tsunenori, Tanabe, Kazunari, Nakayama, Hideki, Horita, Shigeru, Fujita, Takuya, Sugiyama, Yuichi

“…Oseltamivir (Tamiflu®) is a prodrug of Ro 64-0802, a selective inhibitor of influenza virus neuraminidase. There is a possible relationship between oseltamivir…”
Get full text

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study by Ozono, Seiichiro, Tsukamoto, Taiji, Naito, Seiji, Ohashi, Yasuo, Ueda, Takeshi, Nishiyama, Tsutomu, Maeda, Hideki, Kusuoka, Hidehito, Akazawa, Rio, Ito, Mototsugu, Akaza, Hideyuki

“…To evaluate the efficacy and safety of degarelix 3-month depot in Japanese patients with prostate cancer. In this Phase II, open-label, parallel-group study,…”
Get full text

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B receptor, and morphine in recreational opioid users by Ito, Mototsugu, Walzer, Mark, Blauwet, Mary Beth, Spence, Anna, Heo, Nakyo, Kelsh, Debra, Blahunka, Paul, Erdman, Jay, Alsharif, Mohamad Nour, Marek, Gerard J

“…Recent increases in opioid use and subsequent opioid use disorder are a major public health crisis in the United States. This phase 1 randomized,…”
Get full text

Single‐ and multiple‐dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator‐activated receptor delta in healthy adults: Results from a phase 1 study by Ito, Mototsugu, Tauscher‐Wisniewski, Sitra, Smulders, Ronald A., Wojtkowski, Tomasz, Yamada, Akihiro, Koibuchi, Akira, Uz, Tolga, Marek, Gerard J., Goldwater, Ronald D.

“…Introduction/Aims ASP0367, or bocidelpar sulfate, is an orally administered small molecule that potently and selectively modulates peroxisome…”
Get full text

Feasibility of cold snare polypectomy in Japan: A pilot study by Takeuchi, Yoji, Yamashina, Takeshi, Matsuura, Noriko, Ito, Takashi, Fujii, Mototsugu, Nagai, Kengo, Matsui, Fumi, Akasaka, Tomofumi, Hanaoka, Noboru, Higashino, Koji, Iishi, Hiroyasu, Ishihara, Ryu, Thorlacius, Henrik, Uedo, Noriya

“…AIM: To investigate the feasibility of cold snare polypectomy(CSP) in Japan.METHODS: The outcomes of 234 non-pedunculated polyps smaller than 10 mm in 61…”
Get full text

Phosphorylated PKR contributes the induction of GRP94 under ER stress by Ito, Mototsugu, Onuki, Reiko, Bando, Yoshio, Tohyama, Masaya, Sugiyama, Yuichi

“…Phosphorylated double-stranded RNA-dependent protein kinase (PKR) is thought to play an important role during ER stress induced cell death, but its molecular…”
Get full text

Evaluation of [11C]oseltamivir uptake into the brain during immune activation by systemic polyinosine-polycytidylic acid injection: a quantitative PET study using juvenile monkey models of viral infection by Seki, Chie, Oh-Nishi, Arata, Nagai, Yuji, Minamimoto, Takafumi, Obayashi, Shigeru, Higuchi, Makoto, Takei, Makoto, Furutsuka, Kenji, Ito, Takehito, Zhang, Ming-Rong, Ito, Hiroshi, Ito, Mototsugu, Ito, Sumito, Kusuhara, Hiroyuki, Sugiyama, Yuichi, Suhara, Tetsuya

“…Background Abnormal behaviors of young patients after taking the anti-influenza agent oseltamivir (Tamiflu®, F. Hoffmann-La Roche, Ltd., Basel, Switzerland)…”
Get full text